Clinical Trial Update: A Study to Assess the Clinical Efficacy and Safety of Daratumumab in Participants With Relapsed or Refractory Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type [Phase 2]

View source ↗

Summary

Phase 2 clinical trial assessing daratumumab for relapsed or refractory natural killer/T-cell lymphoma, nasal type; study completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Natural Killer T-cell Lymphoma

Drugs mentioned

• Daratumumab (daratumumab)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2021-01-14